Are RNAi and miRNA therapeutics truly dead?

被引：41
|
作者：
Conde, Joao [1 ,2 ]
Artzi, Natalie [1 ,3 ]
机构：
[1] MIT, Harvard Mit Div Hlth Sci & Technol, Inst Med Engn & Sci, Cambridge, MA 02139 USA
[2] Queen Mary Univ London, Sch Engn & Mat Sci, London, England
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol, Boston, MA 02115 USA
来源：
TRENDS IN BIOTECHNOLOGY | 2015年 / 33卷 / 03期
关键词：
RNAi; delivery vehicle; pharmaceutical companies; nanotechnology; biomaterials; SIRNA DELIVERY; DESIGN; POTENT;
D O I：
10.1016/j.tibtech.2014.12.005
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Only a few years ago pharmaceutical companies were excited about the potential of RNA interference (RNAi). Now, financial volatility and subsequent dissolutions of in-house facilities by pharmaceutical companies have had media channels pronouncing that RNAi therapeutics are dead. However, advances in nanomedicine may now help the vast potential of RNAi therapeutics to be fulfilled.
引用
收藏
页码：141 / 144
页数：4
相关论文
共 50 条
  • [21] The Growing Class of Novel RNAi Therapeutics
    Traber, Gavin M.
    Yu, Ai-Ming
    MOLECULAR PHARMACOLOGY, 2024, 106 (01) : 13 - 20
  • [22] RNAi therapeutics: Principles, prospects and challenges
    Aagaard, Lars
    Rossi, John J.
    ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) : 75 - 86
  • [23] Chemical and structural modifications of RNAi therapeutics
    Ku, Sook Hee
    Jo, Sung Duk
    Lee, Yeon Kyung
    Kim, Kwangmeyung
    Kim, Sun Hwa
    ADVANCED DRUG DELIVERY REVIEWS, 2016, 104 : 16 - 28
  • [24] RNAi agents as chikungunya virus therapeutics
    Parashar, Deepti
    Cherian, Sarah
    FUTURE VIROLOGY, 2016, 11 (05) : 321 - 329
  • [25] RNAi therapeutics for the treatment of liver diseases
    Akinc, Akin
    Anderson, Daniel
    Bramlage, Birgit
    Bumcrot, David
    Dorkin, J. Robert
    Fitzgerald, Kevin
    Frank-Kamenetsky, Maria
    Goldberg, Michael
    Harborth, Jens
    Horton, Jay D.
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    John, Matthias
    Rajeev, Kallanthottathil
    Kotelianski, Victor
    Langer, Robert
    Manoharan, Muthiah
    Nechev, Lubomir
    Qin, June
    Racie, Timothy
    Roehl, Ingo
    Sah, Dinah
    Soutschek, Jurgen
    Vornlocher, Hans-Peter
    Zimmermann, Tracy
    Zumbuehl, Andreas
    HEPATOLOGY, 2007, 46 (04) : 800A - 800A
  • [26] A modular platform for targeted RNAi therapeutics
    Kedmi, Ranit
    Veiga, Nuphar
    Ramishetti, Srinivas
    Goldsmith, Meir
    Rosenblum, Daniel
    Dammes, Niels
    Hazan-Halevy, Inbal
    Nahary, Limor
    Leviatan-Ben-Arye, Shani
    Harlev, Michael
    Behlke, Mark
    Benhar, Itai
    Lieberman, Judy
    Peer, Dan
    NATURE NANOTECHNOLOGY, 2018, 13 (03) : 214 - +
  • [27] A modular platform for targeted RNAi therapeutics
    Ranit Kedmi
    Nuphar Veiga
    Srinivas Ramishetti
    Meir Goldsmith
    Daniel Rosenblum
    Niels Dammes
    Inbal Hazan-Halevy
    Limor Nahary
    Shani Leviatan-Ben-Arye
    Michael Harlev
    Mark Behlke
    Itai Benhar
    Judy Lieberman
    Dan Peer
    Nature Nanotechnology, 2018, 13 : 214 - 219
  • [28] RNAi therapeutics: SNALPing siRNAs in vivo
    J J Rossi
    Gene Therapy, 2006, 13 : 583 - 584
  • [29] Biomaterials in RNAi therapeutics: quo vadis?
    Wagner, Ernst
    BIOMATERIALS SCIENCE, 2013, 1 (08) : 804 - 809
  • [30] RNAi therapeutics -: SNALPing siRNAs in vivo
    Rossi, JJ
    GENE THERAPY, 2006, 13 (07) : 583 - 584
12345